Cash Payment and Counseling During Pregnancy
Launched by UNIVERSITY MEDICINE GREIFSWALD · Sep 25, 2020
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how cash rewards and counseling can help pregnant women quit smoking. Smoking during pregnancy can harm both the mother and her unborn baby, so the study aims to find out the best ways to support women in stopping smoking during this important time. Researchers are particularly interested in how small financial incentives can encourage women to successfully quit.
To be eligible for this study, participants must be women who are currently smoking at least one cigarette a day and are between 15 to 23 weeks pregnant. The trial is currently recruiting participants, and it’s important to note that those with language difficulties or cognitive impairments may not be able to take part. If you join the study, you can expect to receive support and rewards aimed at helping you stop smoking, which could lead to a healthier pregnancy for you and your baby.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Current smoking, at least one cigarette per day
- • Pregnancy, between pregnancy week 15 and 23
- Exclusion Criteria:
- • Inadequate language skills
- • Cognitive impairment
About University Medicine Greifswald
University Medicine Greifswald is a prominent academic medical center located in Greifswald, Germany, dedicated to advancing healthcare through innovative research and clinical excellence. As a clinical trial sponsor, it fosters a collaborative environment that integrates cutting-edge scientific inquiry with patient care, focusing on a wide range of medical disciplines. The institution is committed to enhancing patient outcomes by conducting rigorous clinical trials that adhere to the highest ethical standards and regulatory requirements. With a strong emphasis on interdisciplinary collaboration, University Medicine Greifswald aims to contribute significantly to the development of new therapies and medical advancements, ultimately improving healthcare delivery and patient well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Greifswald, , Germany
Patients applied
RH
KS
Trial Officials
Sabina Ulbricht, Prof. Dr.
Principal Investigator
University Medicine Greifswald, Dep. Prevention Research and Social Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials